Dyne Therapeutics Announces Pricing of Initial Public Offering

Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the pricing of its initial public offering of 12,251,578 shares of its common stock at an initial public offering price of $19.00 per share.